Bridgepoint backs PharmaReview

The GP aims to support the company with its growth via the expansion of its geographical presence and its service offering, as well as through investment in the company's team.

Bridgepoint is deploying equity via Bridgepoint Growth I; The GP held a final close for the fund in May 2017 on £86m. The fund makes growth investments of £5-15m, generally targeting consumer, media and technology companies.

When the GP announced its expectation to float, the firm simultaneously announced that it expects to start fundraising for its next Bridgepoint Growth vehicle in the near future.

Company
Founded in 2011 and headquartered in London, PharmaReview supports pharmaceutical and life sciences companies with medical copy and compliance review services. The company aims to ensure that claims made in promotional materials are medically and scientifically accurate, as well as correctly sourced. In addition, PharmaReview aims to ensure that such materials meet legal, ethical and regulatory compliance standards.

People
Bridgepoint – Mayank Kanga (director, Bridgepoint Growth).
PharmaReview – Ralph Carter, Tessa Pugh (co-founders, directors).

Advisers
Equity – Burness Paull (legal); Candesic (commercial due diligence); KPMG (financial due diligence); BDO (tax); Lockton (insurance due diligence).
Vendor – Azets (corporate finance); K&L Gates (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Industrials
• Healthcare
• Bridgepoint
• United Kingdom